Prof Stephen Jackson, University of Cambridge, UK, speaks to ecancertv about cancer treatments that target cells' ability to repair DNA damage. Cells are constantly damaged by influences such as UV light and radiation and consequently have systems in place to repair this damage. Prof Jackson's group developed Olaparib, a drug that targets the PARP repair enzyme in BRCA mutation positive breast or ovarian cancers. Prof Jackson discusses the potential to develop additional drugs that will target different damage repair enzymes which could be used to treat other cancers and talks about the session he will be chairing on this subject at the 2010 NCRI meeting.
